Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites by Hunt, Paul et al.
RESEARCH ARTICLE Open Access
Experimental evolution, genetic analysis and
genome re-sequencing reveal the mutation
conferring artemisinin resistance in an isogenic
lineage of malaria parasites
Paul Hunt
1,2*, Axel Martinelli
1,3, Katarzyna Modrzynska
1, Sofia Borges
4, Alison Creasey
1, Louise Rodrigues
3,
Dario Beraldi
5,10, Laurence Loewe
6, Richard Fawcett
1, Sujai Kumar
7, Marian Thomson
7, Urmi Trivedi
7,
Thomas D Otto
8, Arnab Pain
8,9, Mark Blaxter
5,7, Pedro Cravo
3
Abstract
Background: Classical and quantitative linkage analyses of genetic crosses have traditionally been used to map
genes of interest, such as those conferring chloroquine or quinine resistance in malaria parasites. Next-generation
sequencing technologies now present the possibility of determining genome-wide genetic variation at single base-
pair resolution. Here, we combine in vivo experimental evolution, a rapid genetic strategy and whole genome
re-sequencing to identify the precise genetic basis of artemisinin resistance in a lineage of the rodent malaria
parasite, Plasmodium chabaudi. Such genetic markers will further the investigation of resistance and its control in
natural infections of the human malaria, P. falciparum.
Results: A lineage of isogenic in vivo drug-selected mutant P. chabaudi parasites was investigated. By measuring
the artemisinin responses of these clones, the appearance of an in vivo artemisinin resistance phenotype within the
lineage was defined. The underlying genetic locus was mapped to a region of chromosome 2 by Linkage Group
Selection in two different genetic crosses. Whole-genome deep coverage short-read re-sequencing (Illumina®
Solexa) defined the point mutations, insertions, deletions and copy-number variations arising in the lineage. Eight
point mutations arise within the mutant lineage, only one of which appears on chromosome 2. This missense
mutation arises contemporaneously with artemisinin resistance and maps to a gene encoding a de-ubiquitinating
enzyme.
Conclusions: This integrated approach facilitates the rapid identification of mutations conferring selectable
phenotypes, without prior knowledge of biological and molecular mechanisms. For malaria, this model can identify
candidate genes before resistant parasites are commonly observed in natural human malaria populations.
Background
The molecular basis of drug resistance in malaria para-
sites and its evolution in time and space can be investi-
gated, and possibly controlled, once the genes and
specific mutations involved have been identified. How-
ever, despite intense investigations of human malaria
parasites, few mutations have been unambiguously
linked to drug resistance phenotypes. The most direct
evidence for novel genetic markers comes from classical
genetic studies that require no prior knowledge regard-
ing mode of action or resistance [1]. For example, link-
a g ea n a l y s i so fag e n e t i cc r o s si nPlasmodium
falciparum identified the locus containing pfcrt [2,3], the
determinant of chloroquine resistance. This facilitated
the characterisation of selective sweeps [4] driven by the
world-wide use of chloroquine, and generated insights
into the molecular basis of resistance [5,6]. Genetic stu-
dies have been extended to consider smaller gene
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any medium, provided the original work is properly cited.effects, such as those underlying quinine susceptibility,
by quantitative trait loci analysis [7]. However, there are
experimental and ethical factors that constrain the use
of P. falciparum for genetic studies. For example, it has
sometimes proved difficult to generate drug-resistant P.
falciparum mutant clones in vitro [8] and in these cases
it has been necessary to await the appearance of resis-
tant parasites in field samples. Also, although three
genetic crosses between P. falciparum parasites have
been performed and analysed [9-11] for genes involved
in drug resistance or erythrocyte invasion, these require
primate hosts and are therefore expensive and demand
stringent ethical approval. Fortunately, the experimental
tractability of the rodent malaria P. chabaudi presents a
number of advantages, as follows.
Experimental evolution of the rodent malaria P. cha-
baudi [12] previously produced an isogenic lineage
comprising several genetically stable drug resistant
clones, genetically related to a drug-sensitive clone (AS-
sens, Figure 1), by the repeated in vivo passage of para-
sites in the presence of increasing but sub-curative
doses of the drugs pyrimethamine, chloroquine, meflo-
quine and artemisinin derivatives [13-16]. In general, the
sequence of drug resistance in this lineage reflects the
historical pattern of selection of human malaria parasites
by drug prophylaxis and treatment. Comparisons
between wild-type and isogenic mutant parasites are
especially informative: direct associations (between gen-
otype and phenotype) can be observed in the absence of
additional genetic diversity.
In order to map genes conferring selectable pheno-
types, P. chabaudi h a sa l s ob e e nu s e dt od e v e l o pL i n k -
age Group Selection (LGS) [17], where recombinant
parasites from genetic crosses are analysed en masse;
Figure 1 AS lineage of drug resistant P. chabaudi parasite clones. The cloned isolate AS-sens is sensitive to pyrimethamine (PYR),
chloroquine (CQ), mefloquine (MF), artemisinin (ART) and artesunate. After passage in mice in the presence of PYR (single dose) and
subsequently after multiple passage with increasing sub-lethal doses of CQ, MF, ART or artesunate (blue), surviving parasites were cloned to give
AS-PYR1, AS-3CQ, AS-30CQ, AS-15MF, AS-ATN and AS-ART [13-16,49]. AS-15MF, AS-30CQ and AS-ATN were derived from an uncloned line, AS-
15CQ [14].
♣ Two genetic backcrosses, between the genetically distinct drug-sensitive clone AJ and two members of the AS lineage (AS-15MF,
AS-30CQ), were subjected to Linkage Group Selection (LGS) analysis.
† Clones AS-sens, AS-30CQ and AS-15MF were subjected to whole-genome
re-sequencing. Two specific gene mutations (red) that underlie PYR or ART resistance are shown at positions that indicate their origin within the
lineage. Specific amino-acid substitutions refer to gene predictions in P. chabaudi. The predicted relationship between AS-sens and AS-WTSI is
indicated as co-descendants of the ancestral AS isolate.
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phenotypes of individually cloned recombinant parasites.
LGS scans the genome for ‘selection valleys’;r e g i o n so f
selection where the proportion of alleles from a drug-
sensitive parent are reduced in the uncloned drug-trea-
ted progeny of a genetic cross, relative to those in an
untreated population. This approach has been used to
map genes underlying pyrimethamine resistance [18]
and strain-specific immunity [19,20] in P. chabaudi, and
growth rate in P. yoelii [21].
Now, the advent of next-generation sequencing tech-
nology [22] makes possible whole-genome re-sequencing
of mutant clones [23,24]. Because an annotated P. cha-
baudi AS-sens whole-genome assembly has recently
been made available [25], a comprehensive whole gen-
ome re-sequencing of clones of the AS-lineage (Figure
1) will define all of the genetic variation arising within
the lineage, identify mutations in selection valleys and,
thereby, advance our understanding of the relationships
between genetic mutation, drug response and selection.
This paper integrates these evolutionary, genetic and
genomic approaches to specify the specific mutation
underlying in vivo resistance to artemisinin. We demon-
strate the evolution of artemisinin resistance in the
P. chabaudi AS lineage, use LGS to map an underlying
gene in two independent genetic crosses and re-
sequence the complete genomes of the wild-type AS
parasite and two artemisinin resistant mutants. We con-
clude that a single point mutation in the gene ubp1,
encoding a de-ubiquitinating enzyme, confers artemisi-
nin resistance in this P. chabaudi lineage.
Results
Experimental evolution of artemisinin resistance in
P. chabaudi
The strategy presented here exploits a comprehensive
lineage of genetically related parasites (Figure 1),
comprising drug-resistant mutants previously generated
[13-16] by the sequential passage of parasites in mice
treated with individual drugs (including artemisinin and
artesunate) and the intermittent fixation of mutations by
cloning. We determined the artemisinin responses of
the genetically distinct cloned isolate AJ, and seven
clones of the AS lineage when grown in vivo in mice
(Figure 2). AS-sens, AS-PYR1, AS-3CQ and AJ all failed
to establish detectable parasitaemias after ART treat-
ment (100 mg kg
-1 for 3 days) whereas AS-30CQ, AS-
15MF, and AS-ART gave detectable parasitaemias on
day 8 or 9 post infection and peak parasitaemias of
about 20% at some point between days 12 to 15. AS-
ATN gave detectable parasitaemias on day 12, peaking
a t1 0 %d u r i n gd a y s1 6t o1 7 .A J ,A S - s e n s ,A S - P Y R - 1
and AS-3CQ were deemed artemisinin-sensitive because
no parasites were detected at any time during post-
treatment follow-up. Conversely, because artemisinin
treatment failed for AS-30CQ, AS-15MF, AS-ART and
AS-ATN, these parasites were classified as artemisinin-
resistant. It was therefore predicted that mutations con-
ferring artemisinin resistance were selected between AS-
3CQ and AS-30CQ, AS-ATN or AS-15MF; interestingly,
before parasites were ever exposed to artemisinin deriva-
tives. AS-30CQ parasites had only been exposed to pyri-
methamine and chloroquine, while AS-15MF had also
been exposed to mefloquine. These data suggest that
the gene mutations underlying artemisinin resistance
may have pleiotropic effects. For example they may
affect responses to other drugs such as chloroquine and
mefloquine.
Whole-genome genetic analysis of artemisinin resistance
In order to map the genetic loci underlying artemisinin
resistance, we analysed genetic crosses between either
AS-30CQ (or AS-15MF) (both resistant parasites) and
the genetically distinct drug-sensitive cloned isolate AJ,
Figure 2 Artemisinin resistance phenotype. Artemisinin responses of four resistant and three susceptible AS clones (Figure 1) and AJ, mean of
3 mice. AS-30CQ, AS-ART, AS-ATN and AS-15MF showed artemisinin resistance. AS-3CQ, AS-PYR1, AS-sens and AJ are sensitive.
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(see Methods) between AS-30CQ and AJ (AS-30CQ ×
AJ) were treated with artemisinin (100 mg kg
-1, 3 days).
A genome-wide library of ~100 pyrosequencing assays
[26] was then used to measure the proportions of AJ
and AS alleles (single nucleotide polymorphisms, SNPs)
at pre-mapped loci dispersed across the genome (Addi-
tional File 1) in both the drug-treated and the untreated
populations. A single dominant selection valley was
obtained on chr02 (Figure 3A). For instance, the AJ
allele of the pcpf01-0197 marker here was reduced from
92.1% in the untreated population to 10.1% in the drug-
treated population as shown in a detailed profile of
selection on chr02 (Figure 3B). Except for loci on chr02,
the proportions of AJ alleles of most markers in both
the selected and unselected populations of parasites
were generally high, possibly reflecting the predomi-
nance of AJ alleles in the backcross, the small
Figure 3 Artemisinin resistance genetics. A, Genome-wide scans of LGS of AS-30CQ × AJ backcross (under ART treatment) with quantitation
of parental alleles by pyrosequencing [26]. Comparative Index (AJ) is the proportion of alleles in the population from sensitive parent AJ, after
drug-selection, relative to the proportion measured in untreated hosts. Absence of selection would be represented by a Comparative Index of 1.
Genome position indicates the mapped position (kb) of ~90 markers in the genome of P. chabaudi (Additional File 1). Data points (open green
squares) are each mean of 3 independent determinations. Horizontal line (blue) indicates the threshold for rejecting null hypothesis in simulation
analysis (p < 0.05, Additional File 2). Positions of mutations appearing in both AS-30CQ and AS-15MF as defined by Solexa genome re-
sequencing are indicated at the bottom (x = point mutation; circle = indel). Note one sole point mutation on chr02 (ubp1) and one point
mutation on chr07 (dhfr). Chromosome numbers are indicated (top). B, Position of ART-selection valley on chr02 as determined from two
independent LGS scans of two genetic crosses (AS-30CQ × AJ, red; AS-15MF, × AJ blue) and the position of the mutated gene (ubp1,
PCHAS_020720, green arrow). Pyrosequencing assays shown for whole chromosome (pcpfxx-yyyy, denotes P. chabaudi-specific assays at loci
homologous to P. falciparum chrxx, location yyyy Kbp).
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and/or the existence of many AJ loci contributing small
fitness effects in this experimental system. Factors such
as these render the selection of AS alleles on chr02 even
more striking.
Because apparent genetic associations can arise by
chance, we used two statistical approaches to test the
significance of this selection valley (Methods, Additional
File 2). Firstly, the deepest selection valley from each of
500 simulations (Additional File 3) of the experimental
design were used to estimate the probability (null
hypothesis) that the depth of an observed selection val-
ley was the result of random processes working in com-
bination with selection at minor loci for resistance (p-
value for no major gene = 0.026, Figure 3A, Additional
Files 4, 5). Secondly, the non-parametric Mann-Whitney
U-test was used to evaluate the probability that the
allele frequency observed un d e rd r u g si ss i g n i f i c a n t l y
d i f f e r e n tf r o mt h er a n d o ms c atter of allele frequencies
observed in the absence of drugs. The stringency of the
statistical analysis was increased incrementally by redu-
cing the AJ allele frequencies (AF-reduction) in
untreated parasites (p < 0.001 at 50% AF-reduction,
Additional File 6). Even so, the Mann-Whitney U-test
underestimates the significance of the chr02 selection
valley because the selection valley extended beyond the
5 consecutive loci used to compute significance (7 linked
assays gave low AJ proportions, 4 of which give p <
0.05). Also, chr02 was the most dominant selection val-
ley when a different genetic cross (AS-15MF × AJ) was
selected with 100 mg kg
-1 ART (data not shown) and
the profile of selection on chr02 was similar to that of
the AS-30CQ × AJ cross (Figure 3B). In this case, the
AJ frequency of marker pcpf01-0197 was reduced from
54.2% to 1.0% (Mann-Whitney, p < 0.001 at 25%
AF-reduction).
Whole genome re-sequencing of ART resistant parasites
The dominant chr02 selection valley indicates that both
AS-15MF and AS-30CQ bear a mutation conferring
artemisinin resistance in this locus. Previously, a muta-
tion (V2728F, formerly V770F)) in a ubiquitin-specific
protease (or de-ubiquitinating enzyme) gene (ubp1,
PCHAS_020720) on chr02 was proposed to be linked to
artemisinin resistance [27] but the presence of other
mutations in this locus was not investigated. Here there-
fore, the Illumina® Solexa platform [22] was used to
define a comprehensive inventory of mutations arising
within the P. chabaudi drug-resistant lineage (Methods,
Additional File 7) and specifically, to determine the pre-
sence of other mutations on chr02. We sequenced the
drug-sensitive clone AS-sens and the resistant clones
AS-15MF and AS-30CQ (Table 1). 36 - 41 base single
reads were aligned to the complete and annotated
AS-sens reference genome sequence (AS-WTSI) [25]
using MAQ [28] and SSAHA2 [29] mapping software
packages, producing mean -fold coverage of ~ 39 (AS-
sens), ~54 (AS-15MF) or ~77 (AS-30CQ). AS-WTSI
comprises the majority of the genome assembled into
14 chromosomes, plus a small amount of sequence in
contigs not assigned to any chromosome. The assigned
chromosomal data contains all of the genes that have
orthologues in P. falciparum (in large syntenic blocks
[30]) plus some P. chabaudi- and rodent-specific genes
and expanded gene families primarily located at sub-
telomeric ends of assembled chromosomes. Candidate
SNPs in AS-sens, AS-30CQ or AS-15MF relative to the
AS-WTSI reference sequence were automatically called
by MAQ and SSAHA2 algorithms. This process filters
out unreliable, poor quality SNP calls on the basis of
their associated quality indices and properties (e.g. read
coverage, Phred-like scores, uniqueness and mapping
quality, see Methods and Text S1). Lineage-specific can-
didate mutations were then identified by ‘filtering out’
SNPs specified for AS-30CQ (or AS-15MF) with those
also called for AS-sens. Because artemisinin resistance
arises after AS-3CQ, here we identify only those muta-
tions that are present in both AS-30CQ and AS-15MF.
This set of shared mutations will include those confer-
ring resistance to artemisinin, as well as those conferring
resistance to pyrimethamine and chloroquine.
MAQ and SSAHA2 analysis revealed only four shared
point mutations, located on chr02, chr07, chr11 and chr14
(Table 2, Additional File 8). Their positions relative to the
chr02 selection valley are shown in the genome-wide
genetic scan of artemisinin selected progeny (Figure 3A).
Three of the four point mutations (chr02, chr07, chr11)
are missense mutations in genes with known orthologues
in other Plasmodium spp. The remaining point mutation
is located within an intergenic region on chr14. All four
point mutations were confirmed by di-deoxy sequencing
and their origin within the AS lineage was determined
Table 1 Solexa genome re-sequencing - summary
statistics
AS-30CQ AS-15MF AS-sens
Passage number 71 AS-30CQ 38 AS-15MF 12407 AS-sens
Number of lanes 6 6 4
Read type single-end single-end single-end
Read length (bases) 41 36 36
Nominal fold coverage 30X 30X 20X
% reads mapped to reference sequence
MAQ 97% 90% 91%
SSAHA2 97% 90% 93%
- fold coverage
MAQ 77.91 54.21 39.28
SSAHA2 75.86 53.97 39.48
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Page 5 of 13(Figure 1). Two point mutations (on chr02 and chr07) cor-
responded to genetic changes previously described in the
AS lineage. The point mutation on chr07 in the gene
encoding dihydrofolate reductase (dhfr, PCHAS_072830)
corresponds to a S106N substitution. It arises between
AS-sens and AS-PYR1 and underlies resistance to PYR
[31,32]. The mutation on chr02 is the missense mutation
(V2728F) in ubp1. It arises between AS-3CQ and AS-
30CQ [27] (Figure 1).
This analysis of high-quality SNPs also predicted three
point mutations specific to AS-30CQ and one point
mutation specific to AS-15MF, all on chromosomes
other than chr02 (data not shown). The complete set of
lineage-specific mutations is therefore extremely limited
suggesting that a small number of mutations account
for the evolution of multiple drug resistance phenotypes
in this lineage. Their contribution to other drug-resis-
tance phenotypes (such as chloroquine resistance) will
be evaluated in future investigations.
Five further putative point mutations (in AS-30CQ)
were identified by SSAHA2 but not by MAQ (data not
shown). These putative mutations have markedly lower
quality scores and low relative coverage. One mapped to
ag e n ew i t h o u taP. falciparum orthologue and was
negated by di-deoxy sequencing. The other four mapped
to sub-telomeric or unassigned contigs which have
reduced sequence complexity, increased mapping ambi-
g u i t ya n di n f e r i o rr e f e r e n c es e q u e n c eq u a l i t y .W ew e r e
therefore unable to amplify products from these regions
for di-deoxy sequencing.
Previous sequence analysis of the orthologues of four
candidate genes (atp6, crt, mdr1, tctp) showed that
these were not mutated in AS-ART [16]. As expected,
the genome re-sequencing data presented here showed
that there were no mutations in these genes in AS-
30CQ or AS-15MF either.
A major effect gene conferring artemisinin resistance
was mapped to chr02 by LGS analysis, as described in
the previous section. If the V2728F ubp1 point mutation
is the sole mutation identified on chr02 and if that
mutation arose between the isogenic sensitive and resis-
tant parasite, it must be considered the critical mutation
conferring the resistance phenotype. It was therefore
important to evaluate the possibility that a chr02 muta-
tion had been missed in our analysis.
False negative calls (missedm u t a t i o n s )c o u l db ep r e -
sent in areas with insufficient read coverage and/or
yielding poor mapping quality (e.g. regions containing
low complexity or repetitive sequence). In order to eval-
uate the probable extent of these regions, we analysed
in silico the proportion of the AS-WTSI genome
sequence to which 36 - or 41 base reads could be
mapped uniquely (Additional File 7). These values were
98.63%, and 98.80% respectively (Table 3). For the
experimentally obtained data, 97.78 or 97.95% of the
genome was sequenced at ≥ 5 read coverage for AS-sens
and AS-30CQ respectively (Table 3). These metrics
show that only a small percentage of the genome could
not be re-sequenced with uniquely mapping reads. We
also estimated the proportion of each chromosome
sequence for which the experimental read coverage is
low (≤10). These values range from 0.6% (chr09) to 3.8%
(chr01) (Table 4). These data confirm that the genome
re-sequencing was almost comprehensive and that false
negatives will be confined to < ~ 3% of the genome. We
therefore believe that the number of point mutations
missed by our analysis is likely to be zero or a very
small number, or otherwise restricted to P.chabaudi-
specific expanded gene families, usually located at sub-
telomeric loci. The read-coverage of all nucleotides up
to 200 kbp either side of ubp1 was also investigated.
Here, the proportion of bases with a read-coverage ≤ 10
reads in AS-30CQ was 0.63% (Table 4). Because a read-
coverage of 10 exceeded that sufficient to detect a false
Table 2 Point mutations common to both AS-30CQ and AS-15MF
Chr Ref. seq.
(AS-WTSI)
AS-sens AS-30CQ and AS-15MF Gene ID Substitution Gene abbreviation Annotation
2 C C A PCHAS_020720 V2728F ubp1 de-ubiquitinating enzyme
7 G G A PCHAS_072830 S106N dhfr dihydrofolate reductase
11 G G T - non-synonymous - -
14 T T G - intergenic - -
Table 3 Unique mapping of reads to AS-WTSI reference
sequence
number of
bases
mapped
% of genome sequence (WTSI) mapped
in silico (unique) experimental (unique)
AS AS-30CQ
>=5 >=1 0 >=5 >=1 0
36 mer 18,574,867 98.63 97.78 95.88
41 mer 18,606,976 98.80 97.95 96.96
In silico analysis shows the number of bases and percentage of genome
which can be uniquely mapped by sequence reads (equivalent to theoretical
maximum). Experimental analysis shows the percentage of genome actually
mapped by such reads, at different read-coverages (> = 5, > = 10) in AS-sens
or AS-30CQ. AS-sens and AS-30CQ were analysed with 36 - and 41 base reads,
respectively.
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across the genome in AS-30CQ is so low (~7 point
mutations/~20 Mbases), these data confirm that a false
negative within the selection valley is highly unlikely.
Identification of insertions, deletions and copy number
variants by Solexa re-sequencing
We applied MAQ and SSAHA2 to detect candidate
insertions/deletions (indels) and copy number variants
(CNVs). Full details of this analysis are given in Addi-
t i o n a lF i l e s7 ,9 .T os u m m a r i s e ,w eu s e dS S A H A 2t o
predict small (≤ 3 bp) insertions and deletions (indels),
but no such mutations were confirmed. Analysis of
decreased or increased read coverage can be used to
predict larger deletions and CNVs, respectively. A 34 bp
deletion in an intergenic region of chr07 was confirmed
by di-deoxy sequencing. A potential large (~1 kb) dele-
tion at the right-hand end of chr05 within a rodent
malaria-specific gene (PCHAS_051920) was also identi-
fied but unconfirmed because appropriate DNA frag-
ments could not be amplified and sequenced, probably
because of low-complexity genomic sequence. Specifi-
c a l l y ,t h e r ew e r en op r e d i c t i o n so fi n d e l so rC N V so n
chr02, confirming that these mutation classes are
unlikely to confer artemisinin resistance in AS-30CQ.
Discussion
Ubp1 mutation (V2728F) confers ART resistance
Various lines of evidence confirm that the V2728F ubp1
mutation confers artemisinin resistance. The ubp1
mutation mapped to the bottom of the selection valley
in both genetic crosses analysed (Figure 3B). Solexa re-
sequencing shows that this mutation is the only genetic
variation between resistant and sensitive clones on
chr02. Sanger dideoxy-sequencing confirmed that the
wild-type V2697, V2728 ubp1 haplotype is carried by all
four of the artemisinin-sensitive parasites (AS-sens, AS-
PYR, AS-3CQ and AJ) while V2728F (in AS-30CQ, AS-
ART and AS-15MF) or V2697F (in AS-ATN, formerly
V739F) mutations [27] are borne by parasites with arte-
misinin resistance (Additional File 10 in this lineage of
isogenic parasites. Of the eight point mutations identi-
fied within the AS lineage, those in ubp1 were the only
ones acquired along with the artemisinin resistance phe-
notype (i.e. between AS-3CQ and AS-30CQ, AS-15MF,
or AS-ATN).
The V2728F ubp1 mutation in the AS lineage, was
previously identified [27] but its association with artemi-
sinin resistance was not demonstrated because (i) the
ubp1 mutation in AS-ART arose during the generation
of AS-30CQ under chloroquine selection, and could not
underpin the increase in artemisinin resistance in AS-
ART relative to AS-30CQ, (ii) the selection valley on
chr02 (in the AS-ART × AJ cross) was not sufficiently
dominant with a 25 mg kg
-1 artemisinin selection, and
(iii) the possibility that additional mutations in genes
linked to ubp1 on chr02 could not be excluded. The
present data resolve these ambiguities. Firstly, all clones
(including AS-30CQ, AS-15MF, AS-ATN and AS-ART)
with ubp1 mutations have artemisinin-resistant pheno-
types (100 mg kg
-1, 3 d). Secondly, the chr02 locus is
strongly selected in two different additional independent
crosses by 100 mg kg
-1 artemisinin. Three independent
genetic crosses (using one of the artemisinin-resistant
clones AS-30CQ, AS-15MF (both in this report) or AS-
ART [27]) have now mapped the gene underlying
artemisinin resistance to chr02. Thirdly, whole-genome
re-sequencing confirmed that the point mutation in
ubp1 is the only mutation on chr02.
The cloned parasite AS-ATN (Figures 1, 2) also has an
artemisinin resistance phenotype but contains a different
ubp1 mutation (V2697F) [27]. We propose that the
V2697F ubp1 mutation underlies artemisinin resistance
in AS-ATN too. Formal confirmation of this would
require an LGS analysis to identify a chr02 selection val-
l e yi na nA S - A T N×A Jc r o s s( with respect to artemisi-
nin, or artesunate), and genome re-sequencing of AS-
ATN to confirm that there was no other mutation on
chr02. We believe that both ubp1 mutations arose (in
different parasites) during the production of the
uncloned line AS-15CQ [14] from AS-3CQ under chlor-
oquine selection (Additional File 11). This line was sub-
sequently subjected to further selection by chloroquine
[14], mefloquine [15] or artesunate [16]. Chloroquine
Table 4 AS-30CQ genome coverage by chromosome
Chromosome % coverage >10
Chr01 96.16%
Chr02 98.92%
Chr03 96.32%
Chr04 97.48%
Chr05 97.71%
Chr06 98.04%
Chr07 96.61%
Chr08 99.27%
Chr09 99.39%
Chr10 98.11%
Chr11 98.78%
Chr12 98.88%
Chr13 98.74%
Chr14 98.84%
Total (chrs only) 98.31%
unassigned contigs 71.69%
ubp1 +/-200 kb on chr02 99.37%
*% of nucleotides sequenced by >10 reads
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or near fixation) V2728F ubp1 parasites, while artesu-
nate is thought to have selected V2697F ubp1 parasites.
A full discussion of these issues is included elsewhere
(Additional File 11)
The structural consequences of the V2728F ubp1
mutation in AS-30CQ (and V2697F ubp1 in AS-ATN)
were predicted to be a reduction in de-ubiquitinating
activity [27]. This would increase the proportion of ubi-
quitinated substrate, which may be destined for degrada-
tion through the 26 S proteasome. We suggest that
reduced parasite susceptibility to artemisinin may
involve increased turnover or altered trafficking of a
specific protein or class of proteins (such as membrane
transporters like MDR1, regulators of cell cycle etc.), or
non-specific effects such as a general increased turnover
of proteins damaged by oxidative stress
The model - its generality, application and future
development
The experimental integration of mutant selection,
genetic linkage analysis using LGS, and genome re-
sequencing is a powerful framework for the elucidation
of genetic determinants without prior knowledge of the
underlying biology of the phenotype. The model exploits
the co-incidence between genetically defined selection
valleys and isolated mutations identified by deep gen-
ome re-sequencing. Importantly, it may also confirm the
lack of dominant contributions from additional genes
elsewhere in the genome. The approach complements
reverse genetic validation (transfection) of gene candi-
dates which may be restricted to limited numbers of
pre-defined genes and gene mutations (allelic replace-
ments). Unfortunately, a well-developed transfection
system is currently not available in P. chabaudi.
The approach is applicable to many recombining
organisms for which genome sequence data and experi-
mentally tractable selectable phenotypes are available. In
P. falciparum, there remain difficulties in reliably gener-
ating genetically stable drug-resistant mutants and the
practicality of performing genetic crosses [12]. Neverthe-
less, the approach described here may find applications
in the study of human malaria. For example, a whole-
genome tiling array was used to identify a large amplifi-
cation event in an in vitro selected fosmidomycin-resis-
tant P. falciparum mutant clone [33]. The amplified
fragment included the gene encoding 1-deoxy-D-xylu-
lose-5-phosphate reductoisomerase, the putative target
of fosmidomycin. Deep re-sequencing technologies can
add further resolution to such investigations. Impor-
tantly, in addition, genetic analyses such as LGS also
map the functional relationship between gene locus and
phenotype; critical when elucidating resistance to drugs
for which the mode of action is not well understood.
Pyrosequencing assays were used here to estimate the
proportions of AS and AJ parental alleles and to detect
loci under selection. However, we envisage the future
exploitation of deep short-read sequencing to rapidly
define and quantitate parental SNPs in pooled recombi-
nant parasites (from genetic crosses) before and after
selection. We expect this to improve the detection and
resolution of selection valleys in LGS experiments. It
will also avoid the time required to develop pre-mapped
quantitative parental markers, and permit the use of a
greater range of species and strains.
The genetic basis of multi-drug resistance
The comprehensive genome re-sequencing described
here identified a small number of (mainly non-synon-
ymous) mutations arising in the drug-resistance lineage
of P. chabaudi. These data suggest that complex multi-
drug resistant phenotypes evolved with the accumula-
tion of a relatively small number of mutations, contrary
to some previous speculations [14]. The question arises:
are all of these mutations selected (to fixation or near
fixation) by drugs, or are some mutations neutral and
randomly fixed during cloning by stochastic processes?
Future studies will address this question and evaluate
the extent to which ubp1 and other mutations affect the
responses of these parasites to other drugs such as
chloroquine.
Public health implications
The prediction of genes involved in drug resistance phe-
notypes has important public health implications, espe-
cially when candidate markers are proposed before
resistance is commonly observed in the field, as is the
case for the current study. For example, molecular
genetic markers of resistance are required to monitor
strategies used to contain the spread of resistant para-
sites. At present, we are vulnerable to the evolution of
artemisinin resistance. Indeed, although artemisinin
combination therapies continue to be widely effective,
there have been a number of recent reports document-
ing reduced susceptibilities of malaria parasites to arte-
misinin derivatives in vivo and in vitro, especially in
parts of South-east Asia, such as Western Cambodia
[34-36]. Although genes such as the multi-drug resis-
tance locus, mdr1 [37,38], or pfatp6 [39], encoding an
ATP-ase (SERCA-type), have been proposed to contri-
bute to artemisinin resistance, either these markers have
yet to be confirmed or it is generally believed that they
mediate small effects or reflect responses to the non-
artemisinin partner drug [40,41]. At present therefore,
there are no generally accepted validated markers for
artemisinin resistance-mediated treatment failure.
The ubp1 mutations are the first genetic determinants
to be shown to underlie a distinct change in in vivo
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polymorphisms in the ubp1 orthologue (PFA0220w on
P. falciparum chr01) to in vivo and in vitro artemisinin
responses of P. falciparum parasites can now be
addressed by characterising natural infections and by
transfection studies in the laboratory. For example, a
recent study of parasites from Western Cambodia [42]
showed that there were no corresponding mutations in
ubp1 in artemisinin-resistant P. falciparum parasites.
The data presented here show that, in P. chabaudi,a
single point mutation confers a distinct shift in artemisi-
nin responses. However, whether further mutations in
ubp1 or other genes may confer additional shifts in arte-
misinin response is still uncertain. These possibilities
can be addressed by the generation of multiple indepen-
dently selected resistant clones of P. chabaudi,o rb y
selecting mutants with higher levels of resistance.
Interestingly, artemisinin-resistance and V2728F ubp1
mutations arose in the P. chabaudi isogenic lineage
before the parasites were exposed to artemisinin itself.
Thus, ubp1 mutations may prove to play a role in
multi-drug resistance, as is the case for mdr1 [43].
These relationships are the subject of ongoing investiga-
tions. Although a distinct change in artemisinin
response is described here, observations that in vitro
IC50s of artemisinin derivatives in P. falciparum are
often correlated with those of structurally unrelated
aminoquinolines [44-46] may indicate that similar pro-
cesses occur in human malaria parasites.
The identification of ubp1 mutations will augment our
understanding of artemisinin-resistance mechanisms by
opening up new experimental approaches, such as the
identification of proteins interacting with ubp1.T h i s
may clarify whether artemisinin resistance is mediated
by the modulation of pre-existing drug resistance
mechanisms or by interference with the pathway of arte-
misinin action.
Combination therapies have been proposed to reduce
the probability of selecting (multi-) resistant parasites
[47,48]. This rationale depends upon choosing compo-
nent drugs with different mechanisms of resistance, and
upon the absence of pre-existing resistance to one (or
both) components. The future choice of optimal combi-
nations may be guided by knowledge delivered using a
predictive model such as that presented here.
Conclusion
Experimental evolution of drug resistance, a genome-
wide genetic linkage analysis (LGS) and whole genome
deep re-sequencing have been used to define the muta-
tion conferring artemisinin resistance in the malaria
parasite, P. chabaudi. This system can be used for the
rapid identification of candidate genetic markers of in
vivo drug resistance, before resistance arises in the field.
These data may be used to monitor, understand and
prevent the evolution of drug resistance in the field and
to choose component drugs in combination treatments
designed to maximise drug longevity.
Methods
Parasite lines, maintenance, parasite preparation and
DNA extraction
An u m b e ro fP. chabaudi clones of the AS-lineage
(Figure 1) were used [12-16]. They were routinely inocu-
lated, passaged in CBA mice (4-6 weeks) and cryopre-
served as previously described [49]. Parasites were
prepared and DNA extracted as previously described
[50], ensuring that host white cells were removed by
CF11 cellulose (Whatman, UK) and Plasmodipur filters
(Eurodiagnostica, Netherlands).
Phenotyping, drug tests
Artemisinin drug tests for P. chabaudi parasites have
been previously described [16,27]. Here we used 3 day
treatments on day 1-3 post-inoculation (p.i.) (1 × 10
6
parasites) at the defined doses in CBA mice. Parasitae-
mias were estimated from a drop of blood from the
tail in Giemsa stained thin blood smears as follows.
Infected and uninfected RBCs were counted in up to a
minimum of 2 representative microscope fields (approx
100 RBC/field). Counting of additional fields was
stopped when > 20 infected RBCs had been counted
(maximum 5 fields).
Genetic crosses
The generation of recombinant progeny arising from
genetic crosses between drug-sensitive (AJ) and drug-
resistant (AS lineage) parasites has been previously
described [13,15,18,27]. In the present experiments,
back crosses of both AS-30CQ × AJ and AS-15MF ×
AJ against the sensitive AJ background were performed
in order to maximise the numbers of independent
recombinant parasites and to optimise the resolution
of selection valleys. Previously generated cryopreserved
cross progeny [14,15] were selected with different drug
concentrations (including untreated) and the surviving
parasites at day 5 to day 11 p.i. mixed in approximately
equal proportion with sensitive (AJ) parasites prior to
the genetic backcross procedure. 1 × 10
5 mixed para-
sites were inoculated into C57 mice for production of
gametocytes. Parasites were transmitted on day 5 p.i.
or day 6 p.i. through Anopheles stephensi mosquitoes,
maintained as described previously [49]. Sporozoites
arising in the mosquitoes were recovered by intraperi-
toneal injection, as previously described [13,15,18,27].
Asexual red blood cell forms were collected, pooled
a n du s e dt oi n o c u l a t eC B Am i c eu s e df o rd r u gs e l e c -
tion (LGS) experiments.
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We used pyrosequencing (Biotage) to determine the pro-
portions of parental alleles at many polymorphic sites
across the genome as previously described [26] and
according to the manufacturer’s methodology. In this
study, which pre-dated the release of the full genome
assembly and annotation, the position of individual mar-
kers within the P. chabaudi genome was defined as fol-
lows. The required position of markers within the P.
chabaudi genome was mapped to orthologous genes in
the P. falciparum genome using the rodent malaria syn-
teny maps [30]. Suitable P. falciparum protein sequences
were used to define P. chabaudi sequences in orthologous
genes by TBLASTN analysis, with validation of adjacent
genes in both species. SNPs between AS and AJ parasites
were identified by amplification of nucleotide sequences
from AS and AJ parasites, and assays developed using
high-quality sequence from both clones. Details of the
genome-wide set of assays are given in Additional File 1.
Statistical analysis of genome-wide scans
Overview We developed and used two independent
approaches to assess the statistical significance of puta-
tive selection valleys. The first is based on simulations of
the experimental design and tests the null-hypothesis
that resistance is caused by many loci of small effects and
can therefore not be attributed to one or a few dominant
selection valleys. The second approach compares
observed and corrected allele frequencies in experiments
with and without drug treatment using the non-para-
metric Mann-Whitney U-test. Both approaches have
complementary strengths and weaknesses. Our main goal
is to identify a statistically significant selection valley.
The principles, methodologies, results, model and valida-
tions are detailed in Additional Files 2, 3, 4, 5, 6, 12.
Genome re-sequencing analysis by the Illumina® (Solexa)
platform
Clones AS-sens, AS-15MF and AS-30CQ were re-
sequenced by the Illumina® (Solexa) platform with 36 -
(AS-sens, AS-15MF) or 50 base (AS-30CQ) single reads
(nominal coverage x20, x30, x30 fold respectively) (Table
1). For AS-30CQ, the final 9 base calls were universally
of poor quality and were removed before mapping the
remaining 41 base sequence strings. Individual sequence
strings (reads) from each clone were aligned against an
isogenic AS reference sequence (AS-WTSI, September
2009 assembly, obtained from the publicly available ftp
site of the P. chabaudi AS genome sequencing project
website at the Wellcome Trust Sanger Institute; ftp://ftp.
sanger.ac.uk/pub/pathogens/P_chabaudi/) using two dif-
ferent software packages; MAQ (Mapping and Assembly
with Quality) [28] and SSAHA2 (Sequence Search and
Alignment by Hashing Algorithm) [29].
For SSAHA2 analysis, Solexa reads were mapped
against AS-WTSI using the “pileup” command for single
end reads with the appropriate options as described in
ftp://ftp.sanger.ac.uk/pub/zn1/ssaha_pileup/ssaha_pileup-
readme. Three output files (*.snp, *.ins and *.del) calling
SNPs, insertions or deletions were combined into a single
Artemis [51] - compatible file (*.gff) using a custom
script that further selected SNPs based on a minimum
read coverage that was set at “3” for all the clones, in this
study. A second script was developed to compare the *.
gff files of either of the two mutant clones against the
output obtained for AS-sens. In this way, only mutations
appearing within the AS-lineage were retained. Further-
more, a third custom script was used to filter out all the
remaining SNPs that had ambiguous (or heterozygous)
base calls, where the ‘minority’ base was represented in
≥20% of the total number of reads. The filtered files were
then imported into Artemis which allowed the inspec-
tion, identification and evaluation of these mutations on
the fully annotated genome. For example, mutations
could be immediately identifed as intergenic or intra-
genic, synonymous or non-synonymous etc.
MAQ was used to call point mutations and compared
to those made by SSAHA2. MAQ analysis was performed
using the “easyrun” command in the MAQ software suite
with default parameters, as described in http://maq.sour-
ceforge.net. This generates a list of candidate SNPs for
each clone as a ‘cns.final.snp’ file. These SNPs were sub-
sequently filtered using custom scripts, as follows (see
also Additional File 7). A minimum coverage of 3 reads
was applied to call SNPs in all clones. Proposed SNPs
with ambiguous calls were removed. The SNPs obtained
for mutant clones were then filtered to remove those
SNPs defined for AS-sens. The remaining SNPs are can-
didates for mutations within the AS lineage.
The identification of insertion/deletion mutations
(indels) and CNVs was performed with SSAHA2 using
two approaches, namely SSAHA2’si n t e r n a la l g o r i t h m
for the identification of small indels (≤ 3bp) and a “com-
parative coverage” analysis, both described in detail in
the Additional File 7. Visualisation of individual reads
and coverage which is available in MAQ was used to
confirm indels and CNVs identified by SSAHA2, giving
increased confidence.
Additional material
Additional file 1: Inventory of pyrosequencing assays. The
approximate genome position (column M) of pyrosequencing assays
(columns B-G) are based upon mapping to a previous assembly and
annotation of AS-WTSI, using estimated lengths for telomeres, gaps
between contigs etc. The locus designation pcxxpfyy-zzzz indicates that
the marker maps approximately to P. chabaudi chromosome xx and
homologous to a locus in P. falciparum zzzz kb along chromosome yy
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file describes the statistical methods developed for evaluating whether
selection at given loci is significant. Two methods are described and
evaluated.
Additional file 3: Simulations - examples. Four independent examples
(#1, 9, 10, 12) of simulated genome scans of comparative index (marker
(AJ, drug-sensitive parent) proportion in drug-treated population/ marker
proportion in untreated population) v. genome positions of markers on
14 chromosomes (numbers at top) assuming null hypothesis of 10
resistance (AS advantage, red dots) and 10 fitness (AJ advantage, blue
dots) loci are shown. The z-score (Additional File 2) of the deepest valley
is calculated (bottom left). Additional File 4 plots the frequency of these
z-scores after 500 such simulations. Note that, in contrast to experimental
scans (Figure 3A), many simulations show multiple valleys, including
minor valleys containing only neutral markers.
Additional file 4: Simulations - null distribution histogram. The
distribution of the lowest z-scores was observed in 500 simulations of
selection of the AS-30CQ × AJ cross, using experimental marker
positions. The null hypothesis assumed 10 loci for artemisinin resistance
and 10 minor fitness alleles. The red point indicates the experimentally
observed z-score (-2.364) for chr2 under artemisinin selection (Figure 3A)
corresponding to a p-value of 0.0263. See Additional File 2 for details.
Additional file 5: Simulations - the inferred significance of observed
deepest selection valleys. These data are derived from the simulation
approach. See Additional File 2 for full details.
1 z-score observed in the
experiments;
2 p-value corresponding to the minimum z-score obtained
experimentally;
3 simulations for ART reproduce the experiment that led
to the genome-wide scan in Figure 3A.
Additional file 6: Mann-Whitney analysis of genome-wide LGS. Scan
showing allele frequencies (proportion of AJ allele) from pyrosequencing
after untreated infection (control, black triangles) and treated infection
(artemisinin 100 mg/kg/day, 3 days, red diamonds) (n.b Figure 3A in
main text uses Comparative Index (y-axis, defined in legend Figure 3)
rather than allele proportion used here). Treatment is expected to bias AJ
allele frequencies downward by removing the sensitive parent, AJ and
recombinants free from resistance mutations. To correct for this and
other factors (Text S1), control allele frequencies were reduced before
testing potential selection valleys. Significant valleys are highlighted by
blue circles (P < 0.001 in Mann-Whitney U-tests comparing a sliding
window of 3-5 markers on the same chromosome (treated) with all
untreated markers reduced by the percentage (R) indicated (AF-
reduction); grey triangles show untreated frequencies resulting from a
-25% shift). Positions of this strain’s new mutations found by genome
comparisons are indicated at the bottom (x = SNP; circle = indel).
Chromosome numbers are given at the top. Genome position indicates
physical mapping (Kbp) of 92 markers in the genome of P. chabaudi
(Additional File 1). Data points are each the mean of 3 independent
determinations.
Additional file 7: Solexa whole-genome re-sequencing - extended
methods, results, analysis, evaluation and quality control. This file
includes an extended description of the analysis of the Solexa Illumina
data.
Additional file 8: Point Mutations (shared by AS-30CQ and AS-15MF
wrt AS-sens). This table specifies details of point mutations predicted to
be common to AS-30CQ and AS-15MF.
Additional file 9: Indels and CNVs (shared by AS-30CQ and AS-15MF
wrt AS-sens). This table specifies details of indels and CNVs predicted to
be common to AS-30CQ and AS-15MF.
Additional file 10: Artemisinin, pyrimethamine responses and ubp1,
dhfr mutations in clones of the AS lineage of P. chabaudi. This table
summarises the pyrimethamine and artemisinin responses of various
clones of the lineage and their genotype, with respect to dhfr and ubp1.
Additional file 11: AS-15CQ genotype and the origin of alternative
ubp1 V2697F mutation in AS-ATN. This file discusses a number of
issues regarding AS-15CQ, its non-clonality and the origins of two
mutations in ubp1.
Additional file 12: Validation of simulation - comparing simulation
data and experimental data. This file summarises data which validates
the simulation approach to statistical analysis.
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